Sino-Innovax Biotech

Xiamen Innovax Biotech (Innovax) is a prominent Chinese biotechnology company dedicated to the development and commercialization of high-quality, affordable vaccines. The company achieved global recognition by launching Hecolin, the world's first Hepatitis E vaccine, and Cecolin, China's first domestic HPV vaccine. Innovax leverages a proprietary E. coli-based recombinant protein expression platform, which offers cost-effective and scalable production compared to traditional eukaryotic systems. The company maintains a strategic partnership with GSK for the development of a next-generation 9-valent HPV vaccine. Based in Xiamen, Innovax operates as a key subsidiary within the Yangshengtang Group, focusing on addressing significant public health challenges globally. Its pipeline includes advanced candidates for varicella, rotavirus, and COVID-19, further expanding its impact on infectious disease prevention.